Why an Alzheimer's-focused biotech hoping to 'change the world' shed 70% of its value
October 27, 2021 at 11:18 AM EDT
A clinical trial showed that patients with the greatest reduction in a specific bacterium saw the greatest cognitive benefit from the South San Francisco company's drug, but the trail failed to meet its primary targets.
